TSOI

Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

Retrieved on: 
Monday, March 4, 2024
COVID-19, Research, Infectious Diseases, Stem Cells, Health, Pharmaceutical, Other Science, Science, Oncology, Nerve, SARS-CoV-2, Patent, TSOI, Business development, Virus, Patient, NK, Johns Hopkins University, Long, Cancer, Vaccine

Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19.
  • The Company was previously awarded by the United States Patent and Trademark Office the following QuadraMune® related patents:
    Patent #11,229,674, covering inhibition of the immune suppressing enzyme indolamine 2,3 dioxygenase2.
  • Patent #11,266,707, “Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19”5.
  • Patent #11,504,410, covering use of QuadraMune® and its derivatives for protecting and restoring brain function after neurological damage, including Long COVID6.

Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product

Retrieved on: 
Thursday, February 29, 2024
Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, FDA, TSOI, Standard of care, Cell, GM-CSF, Safety, COVID-19, Patent, Patient, Monocyte, Acute respiratory distress syndrome, Survival, Phase, Science, TGF, Brain, Pharmaceutical industry

Depletion of either of these cells significantly reduced therapeutic effects of JadiCells.

Key Points: 
  • Depletion of either of these cells significantly reduced therapeutic effects of JadiCells.
  • Additionally, transfer of monocytes and T cells from JadiCell treated mice was able to protect naïve mice from lung injury.
  • The therapeutic effect of JadiCells was amplified by administration of Leukine (GM-CSF), which is known to increase circulating monocytes.
  • We are dedicated to curing this terrible disease1 and making our cells the new standard of care.”

Therapeutic Solutions International Files Patent on “Facilitating Effects” of JadiCells on Gene Therapy Mediated Cell Differentiation

Retrieved on: 
Monday, February 26, 2024
Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Animal, Observation, Regenerative medicine, TSOI, Cell, Pharmaceutical industry

Therapeutic Solutions International, Inc. (TSOI), announced today data demonstrating that JadiCell administration is capable of increasing gene therapy mediated production of therapeutic cells in vivo.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today data demonstrating that JadiCell administration is capable of increasing gene therapy mediated production of therapeutic cells in vivo.
  • In a series of experiments the Company showed that animals made deficient in a hormone producing cells can be treated with great efficacy by combining differentiation promoting gene therapy with JadiCell administration.
  • “We are living in a historic time in which gene therapy has been successfully used to change cells within the body of a patient.
  • “We are currently seeking collaborators/licensees to implement this new technology of regenerative gene therapy.”

Therapeutic Solutions International Files Lawsuit in San Diego Superior Court to Obtain Identities of Certain Individuals or Entities

Retrieved on: 
Monday, January 22, 2024
Research, General Health, Professional Services, Internet, Pharmaceutical, Oncology, Technology, Science, Legal, Biotechnology, Finance, Health, Other Science, County, Fraud, ISP, Superior court, Defamation, DOE, StockTwits, Yahoo!, TSOI

Therapeutic Solutions International, Inc. (TSOI), announced the filing of a Civil Action in the Superior Court of the State of California for the County of San Diego to disclose the identities of certain individuals or entities that continuously post defamatory and libelous statements on StockTwits.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced the filing of a Civil Action in the Superior Court of the State of California for the County of San Diego to disclose the identities of certain individuals or entities that continuously post defamatory and libelous statements on StockTwits.
  • The lawsuit filed today by our attorneys is seeking the identities of certain posters in their DOE capacities to learn their true identities, enjoin further defamatory interest communications and recover for the significant injuries TSOI has suffered.
  • Stocktwits.com, InvestorsHub.com Inc., and yahoo.com are websites that provide users the opportunity, through access to their message boards, to communicate with others concerning stock trading, corporate behavior, and other finance-related issues.
  • The websites undoubtedly serve a useful purpose.

Therapeutic Solutions International Launches Adult Stem Cell Therapy Company Focused on Curing Epilepsy

Retrieved on: 
Tuesday, January 16, 2024
Research, Neurology, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Patient, Regenerative medicine, TSOI, Research report, Epilepsy, USD, Intellectual property, Doctor of Philosophy, Encephalitis, Cell, Pharmaceutical industry

Therapeutic Solutions International, Inc. (TSOI) announced the formation of Epilepsy Bio, Inc., a subsidiary company dedicated to commercializing intellectual property, clinical, and mechanistic findings associated with cellular and immunological approaches to epilepsy.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI) announced the formation of Epilepsy Bio, Inc., a subsidiary company dedicated to commercializing intellectual property, clinical, and mechanistic findings associated with cellular and immunological approaches to epilepsy.
  • In October 2022, the Company announced successful treatment of an advanced epilepsy patient using its patented JadiCell universal donor stem cell product1.
  • The Company has subsequently expanded its knowledge of the cellular mechanisms of action using human cells in vitro and animal models.
  • “The immunological aspects of epilepsy cannot be ignored,” said Thomas Ichim, Ph.D., Board Member of the Company, and co-inventor of the epilepsy treatment technology.

Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene™

Retrieved on: 
Wednesday, January 3, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Movement, RU486, FDA, Lung, Disease, TSOI, Cancer, Patient, Pharmaceutical industry

Therapeutic Solutions International, Inc. (TSOI), announced today that its Subsidiary Company Res Nova Biologics, successfully treated four advanced cancer patients with FloraStilbene™.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today that its Subsidiary Company Res Nova Biologics, successfully treated four advanced cancer patients with FloraStilbene™.
  • The patients had no adverse events from drug administration and clinical signals of tumor response were observed.
  • All patients have been followed-up with for more than three months.
  • FloraStilbene™ is a drug comprising of a proprietary formulation of the abortion pill’s active ingredient (RU486) and pterostilbene.

Therapeutic Solutions International Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Protocol, ALS, Interim, IND, Patient, Intellectual property, Survival, TSOI, Pharmaceutical industry

Therapeutic Solutions International, Inc. (TSOI), announced today the formation of ALS Biologics Inc, a subsidiary company dedicated to accelerating development of the Company’s assets related to Amyotrophic Lateral Sclerosis, a progressive motor neuron degenerative disease for which no cure exists.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today the formation of ALS Biologics Inc, a subsidiary company dedicated to accelerating development of the Company’s assets related to Amyotrophic Lateral Sclerosis, a progressive motor neuron degenerative disease for which no cure exists.
  • The company was formed based on previous positive observations in patients treated with the Company’s ALScell™ (JadiCell™) product under the Right to Try Law.
  • “Current treatments offer marginal benefit with the average survival time of patients with ALS being two to five years according to the ALS Association1.
  • “We anticipate IND filing for treatment of ALS on or before the second quarter of 2024.”

Therapeutic Solutions International and Campbell Neurosciences Publish on Nutritional Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Non-Toxic Means of Addressing Depression

Retrieved on: 
Monday, November 27, 2023
Biotechnology, Pharmaceutical, Health, Mental Health, Mental health, Perception, COVID-19, Depression, TSOI, Regenerative medicine, Science, Pharmaceutical industry, Medical device

Therapeutic Solutions International, Inc. (TSOI), announced today a publication with Campbell Neurosciences and several academic institutions describing the importance of the indolamine 2,3 dioxygenase pathway in depression, as well as modulation of this pathway by QuadraMune®, a multi-patented nutraceutical that is commercially available.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today a publication with Campbell Neurosciences and several academic institutions describing the importance of the indolamine 2,3 dioxygenase pathway in depression, as well as modulation of this pathway by QuadraMune®, a multi-patented nutraceutical that is commercially available.
  • “QuadraMune® was developed as an immune stimulator for the prevention and treatment of COVID-19 and was granted several patents for this indication1,2.
  • Subsequently, the science behind QuadraMune® was validated by numerous independent institutions3,4,” said Thomas Ichim, Ph.D., President, and Chief Executive Officer of Campbell Neurosciences and Board Member of Therapeutic Solutions International.
  • Campbell Neurosciences is a subsidiary of Therapeutic Solutions International and has developed a blood-based test for suicidal propensity, as well as several therapeutic approaches to immunologically address mental health.

Therapeutic Solutions International Collaborates on Peer-Reviewed Publication on Personalized Immunotherapy for Brain Cancer Using mRNA

Retrieved on: 
Monday, November 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Immunity, Immune system, Patient, Journal, Immunization, Messenger, Cancer, Immunotherapy, Coronavirus Scientific Advisory Board, TSOI, Publication, Brain, Vaccine

Therapeutic Solutions International, Inc. (TSOI), announced today the publication of a peer-reviewed paper entitled “Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines” which appeared in the November 2023 issue of the Journal of Translational Medicine1.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today the publication of a peer-reviewed paper entitled “Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines” which appeared in the November 2023 issue of the Journal of Translational Medicine1.
  • The article was co-authored by Therapeutic Solutions International Board Member Dr. Thomas Ichim, Chief Scientific Officer Dr. Feng Lin, and Scientific Advisory Board Members Drs Santosh Kesari and Francesco Marincola.
  • In the publication, advances in stimulation of cancer-specific and patient-specific immunity to brain cancer are discussed, as well as methods of augmenting existing immunity.
  • The paper provides several explanations regarding the advantages of mRNA immunization, as well as discusses the means of integrating immunotherapy with other currently used approaches to brain cancer.

Res Nova Biologics Announces First Cancer Patient Treated with FloraStilbene™

Retrieved on: 
Friday, October 20, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, FDA, Patent, RU486, Physician, Exosome, NK, Resveratrol, TSOI, Immunotherapy, Cancer, Patient, Pharmaceutical industry

Therapeutic Solutions International, Inc. (TSOI), announced today the successful first treatment of a patient with FloraStilbene™, a patent pending formulation of the abortion pill’s active ingredient, RU486, and pterostilbene.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today the successful first treatment of a patient with FloraStilbene™, a patent pending formulation of the abortion pill’s active ingredient, RU486, and pterostilbene.
  • In May of this year, Res Nova signed a collaborative agreement with compounding pharmacy Cure Stat Rx for developing a compounded formulation of FloraStilbene™2.
  • “I am extremely proud of the leadership role of Ms. Ramos who in the period of less than a year was able to take FloraStilbene™ from concept to patient.
  • “I am thankful for our translational medicine team that has worked closely with Drs Veltmeyer and Chigurupati for making this first patient treatment a reality,” said Famela Ramos, President, and CEO of Res Nova Bio.